blackthorn
BlackThorn Therapeutics Raises $76M to Personalise Medicine for Mental Disorders
The National Health Service reported that over 70 million prescriptions for antidepressants alone were prescribed in England last year. According to a Scientific American study from 2016, more than one in six US adults takes a psychiatric drug. However, most mental disorders are treated based on symptoms instead of the patient's underlying biology. BlackThorn Therapeutics wants to change that. The AI-based neurobehavioural health startup is using machine learning and artificial intelligence to personalise psychiatric medication.